Kolon Life Science Inc Net Assets

Latest as of September 2025: ₩346.41 Billion KRW ≈ $234.76 Million USD

Kolon Life Science Inc net assets. Based on the latest financial reports, Kolon Life Science Inc (102940) has net assets worth ₩346.41 Billion KRW (≈ $234.76 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩642.14 Billion ≈ $435.17 Million USD) and total liabilities (₩295.72 Billion ≈ $200.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 102940 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩346.41 Billion
% of Total Assets	53.95%
Annual Growth Rate	0.93%
5-Year Change	157.67%
10-Year Change	10.26%
Growth Volatility	59.26

Net Assets of Kolon Life Science Inc (2014–2024)

Net assets of Kolon Life Science Inc from 2014 to 2024. This chart illustrates how Kolon Life Science Inc's net assets have evolved over time, based on quarterly financial data. See 102940 net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Kolon Life Science Inc (2014–2024)

The table below shows the annual net assets of Kolon Life Science Inc from 2014 to 2024. For live market cap and overall valuation, see 102940 company net worth.

Year	Net Assets	Change
2024-12-31	₩149.34 Billion ≈ $101.20 Million	+8.47%
2023-12-31	₩137.67 Billion ≈ $93.30 Million	-17.92%
2022-12-31	₩167.72 Billion ≈ $113.66 Million	+68.72%
2021-12-31	₩99.41 Billion ≈ $67.37 Million	+71.52%
2020-12-31	₩57.96 Billion ≈ $39.28 Million	-42.63%
2019-12-31	₩101.02 Billion ≈ $68.46 Million	-77.36%
2018-12-31	₩446.15 Billion ≈ $302.35 Million	-18.20%
2017-12-31	₩545.41 Billion ≈ $369.62 Million	+109.94%
2016-12-31	₩259.79 Billion ≈ $176.05 Million	+91.81%
2015-12-31	₩135.44 Billion ≈ $91.79 Million	-0.54%
2014-12-31	₩136.17 Billion ≈ $92.28 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Kolon Life Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 397.1% over the analyzed period, potentially due to dividend distributions or operating losses.

Kolon Life Science Inc Net Assets Breakdown (December 2024)

Kolon Life Science Inc net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Common Stock	₩6.21 Billion	4.16%
Other Components	₩371.22 Billion	248.58%
Total Equity	₩149.34 Billion	100.00%

Kolon Life Science Inc Competitors by Market Cap

The table below lists competitors of Kolon Life Science Inc ranked by their market capitalization.

Company	Market Cap
Dongwha Pharm.Co.Ltd KO:000020	$98.05 Million
KEYEAST.Co.Ltd KQ:054780	$98.07 Million
Patriot National Bancorp Inc NASDAQ:PNBK	$98.10 Million
Nicola Mining Inc. American Depositary Shares NASDAQ:NICM	$98.12 Million
DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen XETRA:DAM	$98.03 Million
Logistic Properties of the Americas NYSE MKT:LPA	$98.02 Million
Kewaunee Scientific Corporation NASDAQ:KEQU	$97.92 Million
Samick Thk KO:004380	$97.92 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Kolon Life Science Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 137,671,975,680 to 149,337,504,180, a change of 11,665,528,500 (8.5%).
Net loss of 93,085,909,330 reduced equity.
Share repurchases of 20,000,051,200 reduced equity.
New share issuances of 20,000,051,200 increased equity.
Other factors increased equity by 104,751,437,830.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-93.09 Billion	-62.33%
Share Repurchases	₩20.00 Billion	-13.39%
Share Issuances	₩20.00 Billion	+13.39%
Other Changes	₩104.75 Billion	+70.14%
Total Change	₩-	8.47%

Book Value vs Market Value Analysis

This analysis compares Kolon Life Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.05x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.56x to 1.05x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩22779.79	₩12680.00	x
2017-12-31	₩47824.97	₩12680.00	x
2018-12-31	₩39135.01	₩12680.00	x
2019-12-31	₩8861.31	₩12680.00	x
2020-12-31	₩5083.88	₩12680.00	x
2021-12-31	₩8720.06	₩12680.00	x
2022-12-31	₩14696.63	₩12680.00	x
2023-12-31	₩12063.41	₩12680.00	x
2024-12-31	₩12020.67	₩12680.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Kolon Life Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -62.33%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -57.68%
• Asset Turnover: 0.38x
• Equity Multiplier: 2.81x
Recent ROE (-62.33%) is below the historical average (-22.96%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	4.30%	4.48%	0.63x	1.53x	₩-7.76 Billion
2015	0.59%	0.66%	0.53x	1.69x	₩-12.74 Billion
2016	4.88%	8.00%	0.45x	1.36x	₩-13.31 Billion
2017	-0.26%	-1.19%	0.16x	1.31x	₩-55.94 Billion
2018	-11.36%	-38.20%	0.21x	1.39x	₩-95.30 Billion
2019	-91.39%	-62.15%	0.53x	2.75x	₩-102.43 Billion
2020	-74.53%	-33.38%	0.52x	4.28x	₩-48.99 Billion
2021	-1.38%	-0.83%	0.71x	2.36x	₩-11.32 Billion
2022	1.27%	1.32%	0.51x	1.87x	₩-14.64 Billion
2023	-22.32%	-24.65%	0.40x	2.25x	₩-44.49 Billion
2024	-62.33%	-57.68%	0.38x	2.81x	₩-108.02 Billion

Industry Comparison

This section compares Kolon Life Science Inc's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $101,034,626,727
Average return on equity (ROE) among peers: 12.99%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Kolon Life Science Inc (102940)	₩346.41 Billion	4.30%	0.85x	$98.03 Million
Sam Chun Dang Pharm. Co. Ltd (000250)	$266.11 Billion	-4.10%	0.95x	$2.49 Billion
DongKoo Bio & Pharma Co. Ltd. (006620)	$2.55 Billion	158.01%	22.83x	$21.80 Million
NatureCell Co.Ltd (007390)	$13.75 Billion	13.78%	0.78x	$793.12 Million
Sam-A Pharm. Co. Ltd (009300)	$200.47 Billion	10.66%	0.15x	$56.13 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$259.82 Billion	4.88%	0.12x	$78.42 Million
WooGene B&G Co. Ltd (018620)	$27.27 Billion	-46.89%	2.12x	$46.98 Million
Oscotec Inc (039200)	$21.78 Billion	-9.28%	0.67x	$674.16 Million
EstechPharma Co. Ltd (041910)	$115.63 Billion	3.31%	0.05x	$42.90 Million
Komipharm International Co. Ltd (041960)	$60.02 Billion	-6.63%	0.98x	$343.99 Million
Eagle Veterinary Technology Co.Ltd (044960)	$42.95 Billion	6.15%	0.28x	$25.96 Million

About Kolon Life Science Inc

KQ:102940 Korea Pharmaceuticals

Market Cap

$98.03 Million

₩144.66 Billion KRW

Market Cap Rank

#19074 Global

#915 in Korea

Share Price

₩12680.00

Change (1 day)

-1.32%

52-Week Range

₩12380.00 - ₩70800.00

All Time High

₩163572.85